Home / Investors / Overview

Company Information

CymaBay Therapeutics (NASDAQ: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.  In addition to evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH), our phase 3 ready program for arhalofenate in gout has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update


CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15


CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March

Q4 2017 Quarterly Results